ANVISA Approved New Drug to treat Sly syndrome
Ultragenyx’ Mepsevii has been cleared for use in Europe to treat the ultra rare disease mucopolysaccharidosis type VII (MPS VII), offering patients an approved treatment for the very first time.
Ultragenyx Germany GmbH's Mepsevii (vestronidase alfa) Receives Approval in Europe
Rentschler signs Ultragenyx fill/finish deal for US supply